Q&A

Purdue Pharma joins health policy research organization

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/ajus)
(Image: iStock/ajus)

Related tags: Medicine

Purdue Pharma has joined the National Pharmaceutical Council (NPC), a health policy research organization working to advance good evidence and science.

To learn more about the NPC and Purdue Pharma’s position on the board, Outsourcing-Pharma.com talked with Dr. Tracy Mayne, head of Medical Affairs Strategic Research at Purdue Pharma, who will serve as the company’s representative on the NPC Board of Directors.

Outsourcing-Pharma.com: Why did you decide to join the National Pharmaceutical Council?

Dr. Tracy Mayne:​ The NPC is the preeminent health policy research organization for the industry. NPC is focused on research development and education on important issues to help establish a common understanding of the value of medicines for patients, and supports innovation within the industry.

It is important for Purdue to be a part of that conversation, to help conceptualize and design research that will ultimately define value frameworks for current and future medications. It is exciting for Purdue to be an integral part of NPC’s critical research and innovation.

Outsourcing-Pharma.com: What do you hope to achieve as a member company?

Mayne:​ We hope to be a collaborative partner, exchanging ideas and providing expertise that will help guide NPC’s future research initiatives, with the ultimate goal of ensuring that patients, physicians, payers and pharmaceutical companies have a shared understanding of the value of medicines in today’s healthcare environment.

Outsourcing-Pharma.com: What will your duties include as the company’s representative?

Mayne:​ I will be a member of the NPC Board of Directors. Along with the other board members, I will review and advise on strategic and tactical plans, and provide input on the direction of the NPC research agenda.

Outsourcing-Pharma.com: What are some current issues the industry is facing that the Council will address?

Mayne:​ Value frameworks are an important issue NPC is addressing. They are also working on other issues; for instance, advancing the understanding of patient-centered outcomes research, a component of individualized medicine.

While it is important to understand the broad benefits of medicines for society, it is equally as important to understand the benefit for individual patients, with an overarching goal to ensure that the right medicine reaches the right patient with the right team to provide maximal benefit, and NPC is at the cutting edge of this field of study.

Outsourcing-Pharma.com: Other comments?

Mayne:​ I am honored to be a part of the NPC Board and looking forward to joining this group of distinguished figures in health policy research. They represent some of the most innovative and forward-thinking minds in healthcare.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Related suppliers

Follow us

Products

View more

Webinars